Comprehensive understanding of schizophrenia and its treatment

• Published in: American journal of health-system pharmacy 2002-09, Vol.59 (17 Suppl 5), p.S4-S11
• Main Author: Maguire, Gerald A
• Format: Article
• Language: English
• Subjects: Adult; Depression - psychology; Diagnosis, Differential; Dopamine Antagonists - adverse effects; Dopamine Antagonists - therapeutic use; Humans; Male; Quality of Life; Schizophrenia - diagnosis; Schizophrenia - drug therapy; Schizophrenia - etiology; Serotonin Antagonists - adverse effects; Serotonin Antagonists - therapeutic use; Sex Factors; Suicide - psychology
• ISSN: 1079-2082; 1535-2900
• DOI: 10.1093/ajhp/59.suppl_5.S4

An overview of schizophrenia is presented, including diagnostic criteria, etiology, neurologic findings, pharmacotherapy options, quality-of-life issues, and the financial impact of the disease. Schizophrenia is a chronic disease characterized by positive symptoms, negative symptoms, mood symptoms, and cognitive deficits. Often comorbid substance abuse is present. Schizophrenia accounts for 20% of all hospital bed-days and over 50% of all psychiatric beds in the United States. There is a strong genetic component to schizophrenia, and other possible contributing factors are explored. The diagnostic workup should include a detailed longitudinal history, mental status exam, physical and neurologic exams, and laboratory tests. A magnetic resonance imaging scan can rule out structural causes of psychosis and should be considered at the time of diagnosis. Treatment is based on a biopsychosocial model including pharmacotherapy in combination with individual, group, and family therapies. Rather than classifying antipsychotics as typical or atypical, a new classification scheme has been proposed based on risk of causing extrapyramidal symptoms and tardive dyskinesia (TD), effect on prolactin level, and efficacy profile: first-generation or traditional agents (e.g., chlorpromazine and haloperidol); second-generation agents (e.g., risperidone and ziprasidone); and third-generation agents (e.g., clozapine, olanzapine, and quetiapine). The binding affinities of antipsychotics in the brain help explain the mechanisms by which different antipsychotics alleviate specific symptoms of schizophrenia, as well as cause specific adverse effects. Improved cognition, fewer depressive and mood symptoms, and decreased risk of TD associated with third-generation antipsychotics have improved the quality of life for patients with schizophrenia.